Company profilePharmaceutical#636 of 1,318 in Pakistan2 DRAP alerts

GILLMAN PHARMACEUTICALS

Pharmaceutical company · 17 brands · 20 molecules

Ranked #86 of 156 companies in Antianemic, Iron Preparations

17 registered products 12 pharmaceutical brands 20 distinct molecules 2 DRAP alerts

Company overview

17
registered products
12
pharmaceutical brands
20
distinct molecules
10
therapeutic classes
2
DRAP alerts

GILLMAN PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 17 product registrations across 20 distinct molecules. Its portfolio is concentrated in Antianemic, Iron Preparations and Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by GILLMAN

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antispasmodic & Anticholinergic 1

Top molecules by brand count

Therapeutic classes

Antianemic, Iron Preparations · 2Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Antiinflammatory And Antirheumatic Products · 2Antiemetics & Antinauseants · 1Quinolone Antibacterials · 1Drugs For Treatment Of Bone Diseases · 1Other Beta-Lactam, Cephalosporins & Penems · 1Vitamin A, D & Combinations · 1Antiepileptics · 1Antispasmodic & Anticholinergic · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO1 products · Rs 475 – Rs 475
Median across source: Rs 475

Regulatory record

2 alerts in the DRAP feed we track.

Rapid Alert : Falsified Product Askinoren Gel (Azelaic Acid 15%) Purportedly Manufactured
2024-12-10
Recall Alert: Drug Product; Moxtrex 400mg Tablets (Batch # 850) by M/s Gillman Pharmaceuti
2022-11-07

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 133 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
SHROOQ PHARMACEUTICALS holds 22 molecules not in this portfolio
AcitretinAcyclovirAcyclovir Inf/OralCefiximeCiprofloxacinDiclofenac
MEDERA PHARMACEUTICALS (PVT) LTD. holds 57 molecules not in this portfolio
AcyclovirAmiodaroneAmlodipineArtemetherAzithromycinBenzoyl Peroxide

Get the full profile for GILLMAN

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.